2-Methyl-3-(p-chlorophenyl)-6-diethylaminoethoxybenzofuran Hydrochloride (XVIII). This was prepared like compound XVI in 80% yield, mp 142-144°C (from acetone-ether). Found, %: C 63.39, H 6.33, Cl 17.94. C₂₁H₂₄ClNO₂·HCl. Calculated, %: C 66.50, H 6.40, Cl 18.02.

LITERATURE CITED

- 1. M. Negwer, Organisch-chemische Arzneimittel und ihre Synonyma, Berlin (1967).
- 2. A. N. Grinev, V. I. Shvedov, A. A. Stolyarchuk, et al., Khim. Farm. Zh., No. 6, 142 (1977).
- 3. E. Bisagni and R. Royer, Bull. Chem. Soc. Fr., 925 (1962).
- 4. A. N. Grinev, S. A. Zotova, A. A. Stolyarchuk, et al., Khim. Farm. Zh., No. 1, 51 (1979).
- 5. R. Royer and C. Hudry, Bull. Soc. Chim. Fr., 939 (1961).
- A. N. Grinev, S. A. Zotova, and T. F. Vlasova, Khim. Geterotsikl. Soedin., No. 6, 311 (1976).
- 7. G. N. Pershin, Farmakol. Toksikol., No. 3, 53 (1950).
- 8. V. V. Gatsura, Methods for the Initial Pharmacological Examination of Biologically Active Compounds [in Russian], Moscow (1974).
- 9. N. T. Pryanishnikova and N. A. Sharov, Trimecaine, Pharmacology and Clinical Usage [in Russian], Leningrad (1967).
- 10. R. A. Veits, Farmakol. Toksikol., No. 1, 52 (1951).

SYNTHESIS AND HYPOGLYCEMIC ACTIVITY OF N-ALKYL-N'-(2-AMINO-1,3,4-THIADIAZOL-5-YLSULFONYL)- AND N-ALKYL-N'-(5-SULFAMOYL-1,3,4-THIADIAZOL-2-YL)-OXAMIDES

V. P. Chernykh, Zh. P. Buluda, P. A. Bezuglyi,V. I. Makurina, V. A. Chubenko, and L. N. Voronina

N-Substituted N'-arylsulfonyloxamides display marked sugar-reducing activity and are relatively nontoxic [1-3].

We thought it relevant to structure—activity studies to examine the biological activity of N-alkyl-N'-(2-amino-1,3,4-thiadiazo1-5-ylsulfonyl)- and N-alkyl-N'-(5-sulfamoyl-1,3,4thiadiazo1-2-yl)oxamides, in which the sulfonyl group is attached to a heterocycle.

We synthesized these groups of compounds by the reactions



Khar'kov Pharmaceutical Institute. Translated from Khimiko-Farmatsevticheskii Zhurnal, Vol. 14, No. 2, pp. 33-37, February, 1980. Original article submitted April 23, 1979.

and N-Alkv1-N'-(5-sulfamov1-1.3.4-	
TABLE 1. N-Alkyl-N'-(2-amino-1,3,4-thiadiazol-5-ylsulfonyl)-(III)	thiadiazol-2-y1)-oxamides (V)

	IR spectra, cm ⁻¹	v ^s O2	1180 1175	1170 1180	1175 1179 1175	1180 1170 1175	1170 1180 1170 1175	1180 1170 1170 1175	
		v ^{as} SO ₂	1360 1360	1365 1365	1360 1355 1355	1365 1360 1360	1355 1365 1365 1385 1385	1370 1365 1365 1365 1370	
		°CO	1720 1705	1675 1730	1710 1680 1678	1730 1720 1680	1715 1710 1685 1680 1675	1730 1690 1675 1715 1690	
		ΗΝΛ	3360 3365	3370 3320	3280 3350 3360	3320 3320 3290	3355 3355 3340 3375 3375 3375	3320 3360 3375 3375 3375 3370 3340	
	J Z		$0,32 \\ 0,18$	$0,36 \\ 0,28$	$0,21 \\ 0,44 \\ 0,41 \\ 0,41$	0,39 0,32 0,36	$\begin{array}{c} 0.43\\ 0.25\\ 0.33\\ 0.43\\ 0.57\end{array}$	$0,22 \\ 0,39 \\ 0,37 \\ $	
	oK _a in 60% aqueous lioxane		6,55 6,45	6,68 5;99	5,56 6,63 6,62	5,48 6,72 6,73	6,03 6,06 6,13 6,52 6,52	5,86 5,73 6,573 6,573 6,37	
	μ, d	s	25,52 21,71	$21,86\\21,86$	22,00 20,86 20,86	19,95 19,23 18,78	25,52 24,47 21,71 21,86 21,86	22,01 20,86 19,95 19,23 18,78	
	Calc.	z	27,90 23,71	23,87 23,87	$\begin{array}{c} 24,04\\ 22,78\\ 22,78\\ 22,78\end{array}$	$\begin{array}{c} 21,79\\ 21,00\\ 21,00\\ 20,51 \end{array}$	$\begin{array}{c} 27,90\\ 26,40\\ 23,71\\ 23,87\\ 23,87\\ 23,87\end{array}$	$\begin{array}{c} 24,04\\ 22,78\\ 21,79\\ 21,79\\ 21,00\\ 20,51\end{array}$	
	Formula		$C_4H_5N_5O_4S_2$ $C_6H_9N_5O_5S_2$	${}^{\rm C}_{\rm 7}{}^{ m H_{11}}{}^{ m N_{5}}{}^{ m O_{4}}{}^{ m S_{2}}{}^{ m C}_{\rm 7}{}^{ m H_{11}}{}^{ m N_{5}}{}^{ m O_{4}}{}^{ m S_{2}}{}^{ m s}$	C,H ₉ N ₅ O ₄ S ₂ C ₈ H ₁₃ N ₅ O ₄ S ₂ C ₈ H ₁₃ N ₅ O ₄ S ₂	C ₉ H ₁₅ N ₅ O ₄ S ₂ C ₁₀ H ₁₅ N ₅ O ₄ S ₂ C ₁₁ H ₁₁ N ₅ O ₄ S ₂	C4H 5N 5O4R2 C5H 7N 5O4S2 C6H 9N 5O4S2 C7H11N 5O4S2 C7H11N 5O4S2 C7H11N 5O4S2	C,H ₉ N ₅ O ₄ S ₂ C ₆ H ₁₃ N ₅ O ₄ S ₂ C ₆ H ₁₆ N ₅ O ₄ S ₂ C ₁₀ H ₁₅ N ₅ O ₄ S ₂ C ₁₁ H ₁₁ N ₅ O ₄ S ₂ C ₁₁ H ₁₁ N ₅ O ₄ S ₂	
	1, gr	s	25,73 21,94	21,91 21,90	22,30 20,99 21,01	19,98 19,53 18,93	25,73 24,58 222,80 22,00 21,93	22,13 20,93 20,08 19,47 18,93	
	Found	z	27,98 23,93	23,88 23,99	$\begin{array}{c} 24,30\\ 22,90\\ 22,87\end{array}$	21,87 21,30 20,71	$\begin{array}{c} 27,98\\ 26,48\\ 23,87\\ 23,99\\ 29,88\\ 29,88\end{array}$	$\begin{array}{c} 24,34\\ 22,90\\ 21,90\\ 21,21\\ 20,73\end{array}$	
	Melting point, ^C (aqueous DMF)		$300 \\ 211 - 2$	$220-1 \\ 207-8$	214-5 222-3 230-1	215-6 220-1 221-2	$\begin{array}{c} 215-6\\ 225-6\\ 214-5\\ 229-30\\ 213-4\end{array}$	209—10 223—4 213—4 214—5 214—5 218—9	
	Yield, %		90 78	06 80	76 95 95	73 84 82	96 85 69 85 85 85 85 85 86 85 86 85 86 85 86 85 86 85 86 85 86 85 86 85 86 85 85 85 85 85 85 85 85 85 85 85 85 85	56 56 56 56	
	۲		H CH2CH2OH	C ₃ H ₇ iso-C ₃ H ₇	CH ₂ =CH—CH ₂ C ₄ H ₉ iso-C ₄ H ₉	Iso-C ₅ H ₁₁ cyclo-C ₆ H ₁₁ CH ₂ C ₆ H ₅	H CH3 CH2CH2OH C3H, iso-C3H,	CH ₂ =CHCH ₂ C4H iso-C 5H ₁₁ cyclo:C ₆ H ₁₁ CH ₂ C ₃ H ₅	
	Componind		111a 1111b	IIIc IIId	IIIe IIII f IIII g	III h III j III k	vdc 5 a	۲ کرت کرت	

TABLE 2.	Hypoglycemic	Activity	of	N-Alkyl-N	'-(2-amino-1,3	,4-
thiadiazol	-5-ylsulfonyl	L)- (III) a	and	N-Alkyl-N'	-(5-sulfamoy1-	-
1,3,4-thia	diazol-2-yl)-	-oxamides	(V))		

	Time after administration of the preparation, h							LD ₅₀ , mg/kg	
Compound	2	4	6	8	10	12	24	(intra-	
Compound	reduction in sugar level, % of original							peritoneal)	
(a b l c l d l e l f l f l f l l j l k V a V b V b V d	$ \begin{array}{c} 6\\ 5\\ 4\\ 3\\ 7\\ 12\\ 7\\ 15\\ 14\\ 27\\ 26\\ 8\\ 8\\ 4\\ 4 \end{array} $	8 8 5 9 14 8 20 15 28 24 13 7 9	$7 \\ 13 \\ 8 \\ 8 \\ 11 \\ 14 \\ 8 \\ 22 \\ 12 \\ 28 \\ 25 \\ 14 \\ 19 \\ 8 \\ 8 \\ 14 \\ 19 \\ 8 \\ 10 \\ 10 \\ 10 \\ 10 \\ 10 \\ 10 \\ 10 $	$ \begin{array}{c} 11\\ 10\\ 7\\ 17\\ 10\\ 13\\ 7\\ 32\\ 14\\ 26\\ 26\\ 15\\ 15\\ 10\\ \end{array} $	$ \begin{array}{r} 15 \\ 11 \\ 6 \\ 20 \\ 10 \\ 18 \\ 9 \\ 26 \\ 14 \\ 17 \\ 20 \\ 10 \\ 14 \\ 13 \\ \end{array} $	$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	$ \begin{array}{ c c c c } 4 & 3 \\ 5 & 6 \\ 5 & 6 \\ 8 & 11 \\ 7 & 9 \\ 9 & 5 \\ 4 & 3 \\ \end{array} $	937 728 836 1235 736 628	
ve Vf Vg Vh Vj Vk	5 2 16 21 16 7		10 10 26 27 24 16	12 9 28 25 24 15	$ \begin{array}{c c} 11 \\ 6 \\ 31 \\ 24 \\ 24 \\ 17 \\ \end{array} $	$ \begin{array}{c c} 7 \\ 5 \\ 18 \\ 19 \\ 25 \\ 12 \\ \end{array} $	5 3 15 8 27 7	540 920 !120	
Butamide	21	25	30	24	23	19	5	700	

Reaction of 2-amino-5-sulfamoyl-1,3,4-thiadiazole (I) with diethyl oxalate (in the presence of sodium methoxide) or ethoxalyl chloride gave esters II and IV, respectively, which formed alkylamides III and V with aliphatic amines.

Alkylamides III and V are white crystalline substances, highly soluble in organic solvents and also in alkali solutions.

We verified the homogeneity and structure of the synthetic compounds by elemental analysis, chromatography, and spectroscopy (Table 1).

The IR spectra of alkylamides III and V contain the characteristic stretching bands at 1660-1730 cm⁻¹ (ν_{CO}) and 3290-3375 cm⁻¹ (ν_{NH}). The SO₂ modes appear as two intense bands, at 1170-1180 cm⁻¹ (ν_{SO_2} ^S) and at 1355-1370 cm⁻¹ (ν_{SO_2} ^{as}).

Alkylamides III and V are nitrogen acids. We measured the ionization constants (pK_a) representing proton loss by potentiometric titration in 60% aqueous dioxane. Table 1 shows that the alkyl substituent in the amide part of the molecule only slightly affects the pK_a . As would be expected, the replacement of the aromatic radical by the thiadiazole residue in these substituted oxamides entails a considerable reduction in acidity.

We carried out the biological screening of the synthetic compounds for sugar-reducing activity by the ortho-toluidine method [4] and determined the toxicity in white mice by Litchfield and Wilcoxon's method in M. A. Belen'kii's modification. Our results for compounds III and V are summarized in Table 2 in comparison with butamide.

Table 2 shows that the test compounds have sugar-reducing and hypoglycemic effects, which depend on the nature of the alkyl substituent in the amide part of the molecule. The greatest reduction in blood sugar is caused by the alkylamides III containing the iso-pentyl (IIIh) and benzyl (IIIk) substituents and by compounds Vg, Vh, and Vj, which approach or equal butamide in hypoglycemic activity. Alkylamides IIIh, Vg, and Vj retain their sugar-reducing activity for 24 h, whereas by this time butamide scarcely causes any reduction in the blood sugar level.

Among the test compounds N-cyclohexyl-N'-(5-sulfamoyl-1,3,4-thiadiazole-2-yl)oxamide (Vj) demands particular attention; it causes stable hypoglycemia, which reaches its maximum 6 h after administration and lasts for 24 h. Tests of the acute toxicity revealed that this preparation, like several other compounds, is much less toxic than butamide (Table 2). In general these compounds are inferior in sugar-reducing activity to the preparations currently used for the treatment of diabetes. However, our results will be relevant in further searches for effective preparations among analogs of these compounds.

EXPERIMENTAL CHEMISTRY

The IR spectra were recorded on a UR-20 spectrophotometer in KBr tablets (c 0.5%); pK_a was measured with a pH-340 instrument in aqueous dioxane solution with mmole concentrations of the compounds. Thin-layer chromatography was carried out on Silufol plates in chloroform-methanol (9:1).

Ethyl (2-Amino-1,3,4-thiadiazol-5-ylsulfonyl)oxamate (II). To sodium methylate, prepared from sodium (0.23 g, 0.01 mole) and absolute methanol (25 ml), were added I (1.80 g, 0.01 mole) and dry diethyl oxalate (1.46 g, 0.01 mole). The reaction mixture was kept at room temperature for 1 h. The methanol was stripped off. The residue was diluted with water and filtered. The filtrate was acidified with dilute hydrochloric acid (1:1) to pH5.0 and the precipitate was dried to give II (1.96 g, 70%) with mp 208-210°C (needles; from DMF-ethanol).

Ethyl (5-Sulfamoyl-1,3,4-thiadiazol-2-yl)oxamate (IV). To a solution of I (3.6 g, 0.02 mole) in glacial acetic acid (15 ml) and pyridine (1.74 g, 0.022 mole) was added oxalic acid monochloride monoethyl ester (3.2 g, 0.022 mole) with stirring and cooling. The reaction mixture was stirred for 1 h at the temperature of the boiling water bath. It was then cooled and diluted with water. The precipitate was filtered off and dried to give IV (3.52 g, 63%), mp 203°C (plates; from ethanol).

<u>N-Butyl-N'-(2-amino-1,3,4-thiadiazol-5-ylsulfonyl)oxamide (IIIf)</u>. To a solution of IV (4.2 g, 0.015 mole) in ethanol (20 ml) was added n-butylamine (2.2 g, 0.03 mole). The reaction mixture was kept at room temperature for 12 h. Water (20 ml) was then added and the mixture was acidified with dilute hydrochloric acid (1:1) to pH 5.0. The precipitate was filtered off and dried. Recrystallization gave IIIf (4.38 g, 95%).

Compounds IIIa-e, g-k, and Va-k were prepared in the same way.

EXPERIMENTAL BIOLOGY

We assayed the hypoglycemic activity in male rabbits weighing 2-3 kg. The test compounds were administered perorally through a tube in 2% starch base in a dose of 0.05 g/kg. Blood samples for analysis were taken from an ear vein at various times during the 24 h after a single administration of the preparation. We evaluated the hypoglycemic activity in six to ten rabbits. Blood sugar was determined by the ortho-toluidine method [5] and Hagedorn and Jensen's method [5]. Our results were processed statistically. We made a parallel assay of the effect of butamide to compare sugar-reducing activity.

LITERATURE CITED

- 1. V. P. Chernykh, I. P. Vannyi, T. S. Dzhan-Temirova, et al., Khim. Farm. Zh., No. 9, 49 (1978).
- 2. V. P. Chernykh, I. P. Bannyi, V. I. Makurina, et al., Khim. Farm. Zh., No. 12, 79 (1978).
- 3. V. P. Chernykh, V. I. Makurina, I. M. Timasheva, et al., Farm. Zh., No. 6, 47 (1978).
- 4. A. V. Raitsis and A. O. Ustinova, Lab. Delo, No. 1, 33 (1965).
- 5. N. N. Pushkina, Biochemical Methods of Testing [in Russian], Moscow (1963), pp. 97-102.